



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

April 3, 2018

Via E-mail

James C. Clemmer  
President and Chief Executive Officer  
AngioDynamics, Inc.  
14 Plaza Drive, Latham  
New York 12110

**Re: AngioDynamics, Inc.**  
**Form 10-K for the Fiscal Year Ended May 31, 2017**  
**Filed August 4, 2017**  
**File No. 0-50761**

Dear Mr. Clemmer:

We refer you to our comment letter dated January 4, 2018, regarding business contacts with Sudan and Syria. We have completed our review of this subject matter. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

/s/ Cecilia Blye

Cecilia Blye, Chief  
Office of Global Security Risk

cc: Amanda Ravitz  
Assistant Director  
Division of Corporation Finance